Allogene, Servier’s ‘off-the-shelf’ CAR-T shows high response rate in Phase I lymphoma data at ASCO

Allogene, Servier’s ‘off-the-shelf’ CAR-T shows high response rate in Phase I lymphoma data at ASCO

While cautioning that it’s still early days, experts said the data – especially those showing much lower toxicity – raise the tantalizing prospect that the therapy could replace autologous CAR-Ts, if its efficacy remains the same.

Source: https://ift.tt/3ckEKOQ